Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention

Susanna Esposito, Luca Castellazzi, Annalisa Bosco, Alessandra Musio, Jeffrey Stoddard

Research output: Contribution to journalArticlepeer-review

Abstract

Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal antigens using reverse vaccinology, a technique that predicts likely vaccine candidates using computational analysis of the whole bacterial genome. This has resulted in a multicomponent, recombinant, meningococcal serogroup B vaccine: 4CMenB (Bexsero®, Novartis Vaccines & Diagnostics, NC, USA), containing four main immunogenic components: two recombinant fusion proteins (Neisseria heparin-binding antigen-GNA1030 and factor H-binding protein-GNA2091); recombinant Neisserial adhesion A; and detergent-treated outer membrane vesicles derived from the meningococcal NZ98/254 strain, where porin A 1.4 is the major immunodominant antigen. In this article, we summarize the available clinical data on 4CMenB in healthy infants, adolescents and adults, and discuss the methods available for assessing vaccine efficacy.

Original languageEnglish
Pages (from-to)395-408
Number of pages14
JournalImmunotherapy
Volume6
Issue number4
DOIs
Publication statusPublished - 2014

Keywords

  • meningitis
  • meningococcal B vaccine
  • Neisseria meningitidis
  • prevention

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention'. Together they form a unique fingerprint.

Cite this